keyword
MENU ▼
Read by QxMD icon Read
search

PDAC blood markers

keyword
https://www.readbyqxmd.com/read/30080739/circulating-tumor-cells-dynamics-in-pancreatic-adenocarcinoma-correlate-with-disease-status-results-of-the-prospective-cluster-study
#1
Georgios Gemenetzis, Vincent P Groot, Jun Yu, Ding Ding, Jonathan A Teinor, Ammar A Javed, Laura D Wood, Richard A Burkhart, John L Cameron, Martin A Makary, Matthew J Weiss, Jin He, Christopher L Wolfgang
OBJECTIVES: Previous retrospective studies demonstrated that circulating tumor cells (CTCs) subtypes correlate with overall survival in patients with pancreatic ductal adenocarcinoma (PDAC). Herein, we report results of a prospective observational study on CTCs dynamics to assess their clinical significance. METHODS: The CLUSTER study is a prospective longitudinal study on PDAC CTCs dynamics (NCT02974764). Multiple peripheral blood samples were collected from 200 consecutively enrolled patients with presumed PDAC diagnosis...
September 2018: Annals of Surgery
https://www.readbyqxmd.com/read/29945294/periostin-and-ca242-as-potential-diagnostic-serum-biomarkers-complementing-ca19-9-in-detecting-pancreatic-cancer
#2
Dong Dong, Li Jia, Lufang Zhang, Na Ma, Aimin Zhang, Yunli Zhou, Li Ren
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with few biomarkers to guide treatment options. Carbohydrate antigen 19.9 (CA19.9), the most frequently used biomarker for PDAC, is not sensitive and specific enough for the detection of the disease. This study aimed to evaluate serum periostin (POSTN) and CA242 as potential diagnostic biomarkers complementing CA19.9 in detecting pancreatic cancer. Blood samples were from 362 participants, including 213 patients with different stages of PDAC, 75 patients with benign pancreatic disease, and 74 healthy individuals...
June 26, 2018: Cancer Science
https://www.readbyqxmd.com/read/29709702/tumor-released-exosomal-circular-rna-pde8a-promotes-invasive-growth-via-the-mir-338-macc1-met-pathway-in-pancreatic-cancer
#3
Zhonghu Li, Wu Yanfang, Jie Li, Peng Jiang, Tao Peng, Kai Chen, Xin Zhao, Yujun Zhang, Ping Zhen, Jin Zhu, Xiaowu Li
Circular RNA (circ-RNA) and exosomes have recently been shown to play important roles in different tumors. However, the functions and regulatory mechanisms of exosomal circ-RNA in pancreatic ductal adenocarcinoma (PDAC) tumor progression remain unclear. Here, we identified a circular RNA (circ-PDE8A) from liver-metastatic PDAC cells by microarray analysis, detected its expression levels in clinical tissues and found that high circ-PDE8A expression was correlated with lymphatic invasion, TNM stage and a poor survival rate of PDAC patients...
September 28, 2018: Cancer Letters
https://www.readbyqxmd.com/read/29526691/analysis-of-cell-free-dna-to-assess-risk-of-tumoremia-following-endoscopic-ultrasound-fine-needle-aspiration-of-pancreatic-adenocarcinomas
#4
Michael J Levy, Benjamin R Kipp, Dragana Milosevic, Amber R Schneider, Jesse S Voss, Rajeswari Avula, Sarah E Kerr, Michael R Henry, Edward Highsmith, Minetta C Liu, Ferga C Gleeson
BACKGROUND & AIMS: Cellular and nuclear material from tumors disseminates into the bloodstream (tumoremia), but it is not clear whether medical procedures cause release of this material or contribute to formation of metastases. We performed a prospective study of blood samples from patients with pancreatic adenocarcinoma (PDAC) to determine whether endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) associates with markers of tumoremia. METHODS: We obtained peripheral blood from 104 patients (35 with PDAC) before and after EUS-FNA of primary tumors; blood samples from 69 healthy individuals were used as controls...
March 8, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29248440/jtc801-induces-ph-dependent-death-specifically-in-cancer-cells-and-slows-growth-of-tumors-in-mice
#5
Xinxin Song, Shan Zhu, Yangchun Xie, Jiao Liu, Lingyi Sun, Dexing Zeng, Pengcheng Wang, Xiaochao Ma, Guido Kroemer, David L Bartlett, Timothy R Billiar, Michael T Lotze, Herbert J Zeh, Rui Kang, Daolin Tang
BACKGROUND & AIMS: Maintenance of acid-base homeostasis is required for normal physiology, metabolism, and development. It is not clear how cell death is activated in response to changes in pH. We performed a screen to identify agents that induce cell death in a pH-dependent manner (we call this alkaliptosis) in pancreatic ductal adenocarcinoma cancer (PDAC) cells and tested their effects in mice. METHODS: We screened a library of 254 compounds that interact with G-protein-coupled receptors (GPCRs) to identify those with cytotoxic activity against a human PDAC cell line (PANC1)...
April 2018: Gastroenterology
https://www.readbyqxmd.com/read/29199604/mirna-a-diagnostic-and-therapeutic-tool-for-pancreatic-cancer
#6
REVIEW
Muhammad Imran Qadir, Arooj Faheem
Pancreatic ductal adenocarcinoma (PDAC) is fatal disease and one of the major causes of death among cancer patients. Diagnosis of PDAC during the early stages of cancer using ultrasounds and blood tests is difficult and chemotherapies alone for treating cancers are not very effective. MicroRNAs (miRNAs), small non-coding RNAs that alter the expression of genes in many processes, have been identified to play a significant role in pancreatic cancer regulation. miRNAs are classified as oncomiRs (tumor inducers) and tumor suppressor miRNAs...
2017: Critical Reviews in Eukaryotic Gene Expression
https://www.readbyqxmd.com/read/28978057/hyal2-methylation-in-peripheral-blood-as-a-potential-marker-for-the-detection-of-pancreatic-cancer-a-case-control-study
#7
Sarah Schott, Rongxi Yang, Sarah Stöcker, Federico Canzian, Nathalia Giese, Peter Bugert, Frank Bergmann, Oliver Strobel, Thilo Hackert, Christof Sohn, Barbara Burwinkel
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy which is mostly diagnosed in advanced and inoperable stages though surgery remains the only curable therapeutic approach. Early detection markers are urgently needed to improve diagnosis. Altered hyaluronoglucosaminidase 2 gene (HYAL2) DNA methylation in peripheral blood is known to be associated with malignancy at early stage but has not been evaluated in PDAC patients. This study evaluates the association between blood-based HYAL2 methylation and PDAC by a case-control study with 191 controls and 82 PDAC patients...
September 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28957348/-stealth-dissemination-of-macrophage-tumor-cell-fusions-cultured-from-blood-of-patients-with-pancreatic-ductal-adenocarcinoma
#8
Gary A Clawson, Gail L Matters, Ping Xin, Christopher McGovern, Eric Wafula, Claude dePamphilis, Morgan Meckley, Joyce Wong, Luke Stewart, Christopher D'Jamoos, Naomi Altman, Yuka Imamura Kawasawa, Zhen Du, Loren Honaas, Thomas Abraham
Here we describe isolation and characterization of macrophage-tumor cell fusions (MTFs) from the blood of pancreatic ductal adenocarcinoma (PDAC) patients. The MTFs were generally aneuploidy, and immunophenotypic characterizations showed that the MTFs express markers characteristic of PDAC and stem cells, as well as M2-polarized macrophages. Single cell RNASeq analyses showed that the MTFs express many transcripts implicated in cancer progression, LINE1 retrotransposons, and very high levels of several long non-coding transcripts involved in metastasis (such as MALAT1)...
2017: PloS One
https://www.readbyqxmd.com/read/28916969/comparison-of-platelet-lymphocyte-ratio-and-ca-19-9-in-differentiating-benign-from-malignant-head-masses-in-patients-with-chronic-pancreatitis
#9
COMPARATIVE STUDY
Shanavas Kakkat, Ramesh Rajan, R S Sindhu, Bonny Natesh, S Raviram
INTRODUCTION: Pancreatic head ductal adenocarcinoma (PDAC) and inflammatory head masses (IHM) related to chronic pancreatitis are often difficult to differentiate. PDAC produces significant inflammatory response with resultant lymphopenia and thrombocytosis. The prognostic role of platelet-lymphocyte ratio (PLR) as a tumor marker has been defined. We aimed to find the role of PLR as a diagnostic marker for PDAC in differentiating benign head mass comparing with carbohydrate antigen 19-9 (CA 19-9)...
July 2017: Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology
https://www.readbyqxmd.com/read/28782087/germline-brca-mutations-in-asian-patients-with-pancreatic-adenocarcinoma-a-prospective-study-evaluating-risk-category-for-genetic-testing
#10
Kyoungmin Lee, Changhoon Yoo, Kyu-Pyo Kim, Kyoung-Jin Park, Heung-Moon Chang, Tae Won Kim, Jae-Lyun Lee, Woochang Lee, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Dong Wan Seo, Sung Koo Lee, Myung-Hwan Kim, Sang Hyun Shin, Dae Wook Hwang, Ki Byung Song, Jae Hoon Lee, Song Cheol Kim, Baek-Yeol Ryoo
Introduction Germline BRCA mutations may have therapeutic implications as surrogate markers of DNA-damage repair status in pancreatic ductal adenocarcinoma (PDAC). We performed a prospective study to evaluate the efficiency of risk criteria based on personal or family history of breast and ovarian cancer for determining germline BRCA mutations in PDAC patients with Asian ethnicity. Methods Between November 2015 and May 2016, we screened consecutive PDAC patients with locally advanced unresectable or metastatic disease who were referred for systemic chemotherapy...
February 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/28739842/new-biomarker-identified-for-pdac
#11
(no author information available yet)
A new study suggests that the protein THBS2 could lead to early detection of pancreatic ductal adenocarcinoma. By testing for THBS2 and another marker, CA19-9, researchers identified blood samples from patients with the disease with 98% specificity and 87% sensitivity.
September 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28701476/detection-of-early-pancreatic-ductal-adenocarcinoma-with-thrombospondin-2-and-ca19-9-blood-markers
#12
Jungsun Kim, William R Bamlet, Ann L Oberg, Kari G Chaffee, Greg Donahue, Xing-Jun Cao, Suresh Chari, Benjamin A Garcia, Gloria M Petersen, Kenneth S Zaret
Markers are needed to facilitate early detection of pancreatic ductal adenocarcinoma (PDAC), which is often diagnosed too late for effective therapy. Starting with a PDAC cell reprogramming model that recapitulated the progression of human PDAC, we identified secreted proteins and tested a subset as potential markers of PDAC. We optimized an enzyme-linked immunosorbent assay (ELISA) using plasma samples from patients with various stages of PDAC, from individuals with benign pancreatic disease, and from healthy controls...
July 12, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/28674438/pancreatic-cancer-circulating-tumor-cells-and-primary-tumors-show-heterogeneous-kras-mutations
#13
Birte Kulemann, Stephanie Rösch, Sindy Seifert, Sylvia Timme, Peter Bronsert, Gabriel Seifert, Verena Martini, Jasmina Kuvendjiska, Torben Glatz, Saskia Hussung, Ralph Fritsch, Heiko Becker, Martha B Pitman, Jens Hoeppner
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease. Circulating tumor cells (CTC) in the blood are hypothesized as the means of systemic tumor spread. Blood obtained from healthy donors and patients with PDAC was therefore subject to size-based CTC-isolation (ISET). We additionally compared Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in pancreatic CTC and corresponding tumors, and evaluated their significance as prognostic markers. Samples from 68 individuals (58 PDAC patients, 10 healthy donors) were analyzed; CTCs were present in patients with UICC stage IA-IV tumors and none of the controls (p < 0...
July 3, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28413374/discrimination-of-pancreatic-cancer-and-pancreatitis-by-lc-ms-metabolomics
#14
Anna Lindahl, Rainer Heuchel, Jenny Forshed, Janne Lehtiö, Matthias Löhr, Anders Nordström
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is the fifth most common cause of cancer-related death in Europe with a 5-year survival rate of <5%. Chronic pancreatitis (CP) is a risk factor for PDAC development, but in the majority of cases malignancy is discovered too late for curative treatment. There is at present no reliable diagnostic marker for PDAC available. OBJECTIVES: The aim of the study was to identify single blood-based metabolites or a panel of metabolites discriminating PDAC and CP using liquid chromatography-mass spectrometry (LC-MS)...
2017: Metabolomics: Official Journal of the Metabolomic Society
https://www.readbyqxmd.com/read/28376157/sequential-validation-of-blood-based-protein-biomarker-candidates-for-early-stage-pancreatic-cancer
#15
Michela Capello, Leonidas E Bantis, Ghislaine Scelo, Yang Zhao, Peng Li, Dilsher S Dhillon, Nikul J Patel, Deepali L Kundnani, Hong Wang, James L Abbruzzese, Anirban Maitra, Margaret A Tempero, Randall Brand, Matthew A Firpo, Sean J Mulvihill, Matthew H Katz, Paul Brennan, Ziding Feng, Ayumu Taguchi, Samir M Hanash
Background: CA19-9, which is currently in clinical use as a pancreatic ductal adenocarcinoma (PDAC) biomarker, has limited performance in detecting early-stage disease. We and others have identified protein biomarker candidates that have the potential to complement CA19-9. We have carried out sequential validations starting with 17 protein biomarker candidates to determine which markers and marker combination would improve detection of early-stage disease compared with CA19-9 alone. Methods: Candidate biomarkers were subjected to enzyme-linked immunosorbent assay based sequential validation using independent multiple sample cohorts consisting of PDAC cases (n = 187), benign pancreatic disease (n = 93), and healthy controls (n = 169)...
April 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/27789528/circulating-tumor-cells-expressing-markers-of-tumor-initiating-cells-predict-poor-survival-and-cancer-recurrence-in-patients-with-pancreatic-ductal-adenocarcinoma
#16
Katherine E Poruk, Amanda L Blackford, Matthew J Weiss, John L Cameron, Jin He, Michael Goggins, Zeshaan A Rasheed, Christopher L Wolfgang, Laura D Wood
Purpose: Circulating tumor cells (CTCs) have been identified in the blood of patients with pancreatic adenocarcinoma (PDAC), but little is known about the exact phenotype of these cells. We assessed expression of aldehyde dehydrogenase (ALDH), CD133, and CD44 as markers of CTCs with a tumor-initiating cell (TIC) phenotype in patients with PDAC and the relationship of this expression to patient outcomes. Experimental Design: Peripheral blood from 60 consecutive patients with PDAC undergoing surgical resection was obtained and processed using the Isolation by Size of Epithelial Tumor (ISET) method...
June 1, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27623556/identification-of-novel-serum-autoantibodies-for-differential-diagnosis-of-autoimmune-pancreatitis-and-pancreatic-ductal-adenocarcinoma
#17
Klaus Felix, Oliver Hauck, Martina Schnölzer, Tore Kempf, Uwe Warnken, Kathrin Schneider, Frank Bergmann, Stefan Fritz, Jens Werner
OBJECTIVES: The lack of specific biochemical markers is a major drawback for the diagnosis of autoimmune pancreatitis (AIP). The aims were to characterize the autoantibody profiles in AIP and pancreatic ductal adenocarcinoma (PDAC) and to identify circulating autoantibodies that could be diagnostic markers differentiating PDAC and the AIP subtypes. METHODS: Tissue lysates obtained from the resected pancreas of patients with AIP and patients with PDAC were separated by 2-dimensional polyacrylamide gel electrophoresis subsequently immunoblotted with autologous sera...
October 2016: Pancreas
https://www.readbyqxmd.com/read/27546476/diabetes-associated-with-pancreatic-ductal-adenocarcinoma-is-just-diabetes-results-of-a-prospective-observational-study-in-surgical-patients
#18
Erica Dugnani, Alessandra Gandolfi, Gianpaolo Balzano, Marina Scavini, Valentina Pasquale, Francesca Aleotti, Daniela Liberati, Gaetano Di Terlizzi, Giovanna Petrella, Michele Reni, Claudio Doglioni, Emanuele Bosi, Massimo Falconi, Lorenzo Piemonti
BACKGROUND: Identification of a specific diabetes signature associated to pancreatic ductal carcinoma (PDAC) could be a key to detect asymptomatic, early stage tumors. We aim to characterize the clinical signature and the pathogenetic factors of the different types of diabetes associated with PDAC, based on the time between diabetes and cancer diagnosis. METHODS: Prospective observational study on 364 PDAC patients admitted to a referral center for pancreatic disease...
September 2016: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]
https://www.readbyqxmd.com/read/27539232/circulating-micrornas-as-potential-diagnostic-prognostic-and-therapeutic-targets-in-pancreatic-cancer
#19
REVIEW
Safieh Ebrahimi, Mina Hosseini, Faezeh Ghasemi, Soodabeh Shahidsales, Mina Maftouh, Hamed Akbarzade, Seyed Ali Reza Parizadeh, Seyed Mahdi Hassanian, Amir Avan
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a very poor prognosis, and excessive resistance to chemotherapy. MicroRNAs have been shown to play important roles in PDAC oncogenesis as they can act as both oncogenes and tumor suppressor molecules. Altered expression of specific microRNAs in PDAC has diagnostic and prognostic implications. There is growing body of evidence showing the important role of miR-486-5p and miR-938 for discrimination of PDAC patients from healthy subjects and those with chronic pancreatitis...
2016: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/27442667/the-significance-of-relative-dose-intensity-in-adjuvant-chemotherapy-of-pancreatic-ductal-adenocarcinoma-including-the-analysis-of-clinicopathological-factors-influencing-relative-dose-intensity
#20
Norimitsu Yabusaki, Tsutomu Fujii, Suguru Yamada, Kenta Murotani, Hiroyuki Sugimoto, Mitsuro Kanda, Goro Nakayama, Masahiko Koike, Michitaka Fujiwara, Yasuhiro Kodera
Recently, it has been reported that the relative dose intensity (RDI) of adjuvant chemotherapy (AC) influences survival in various cancers, but there are very few reports about RDI in pancreatic ductal adenocarcinoma (PDAC). The optimal timing for initiation of AC for PDAC also remains unknown. The aim of this study was to identify the significance of RDI and the time interval between surgery and initiation of AC on survival of patients with PDAC. Clinicopathological factors that affect RDI were also investigated...
July 2016: Medicine (Baltimore)
keyword
keyword
166055
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"